In this issue:
MUSETTE & GAVOTTE: bodyweight-adjusted high-dose ocrelizumab in relapsing MS & PPMS
ORATARIO-HAND: ocrelizumab in a broad population of PPMS
Telomeres & biological ageing in paediatric-onset MS
Machine-learning models to predict progression
DMTs in late-onset vs. adult-onset RRMS
ULTIMATE I/II: ublituximab vs. teriflunomide in highly active relapsing MS
Post-partum disease activity with intravenous vs. subcutaneous natalizumab
MS-STAT2: simvastatin & disability progression in SPMS
Hospital time with intravenous vs. subcutaneous ocrelizumab
TOP: long-term natalizumab in real-world RRMS
Please login below to download this issue (PDF)